Clinical Trials And ResearchThe Iomab-ACT approach has shown positive data on safety and tolerability, as well as good response rates in a small Phase 1 study at Memorial Sloan Kettering.
Regulatory And Market PotentialActinium will focus its efforts and deploy capital on continuing development of Actimab-A, Iomab-ACT, preclinical radiopharmaceutical programs, and Ac-225 manufacturing initiatives, which are seen as sources of potential upside to investors.
Strategic InitiativesActinium Pharmaceuticals announced a multi-million-dollar investment in a strategic initiative to support the development and deployment of its cyclotron-based method of manufacturing high-purity alpha-emitting Actinium-225, potentially reducing costs by 10-20 times.